MGH Cancer Center Grand Rounds 2022-2023: Archived

Description

This activity provides on-demand archived lectures from the MGH Cancer Center Grand Rounds 2022-2023 series. As one of the leading academic cancer centers in the country, our research and clinical staff need to be educated on cutting edge information on advances and perspectives on cancer research and treatment across the full spectrum of cancer specialization. This will help clinicians understand, assess and apply this information in our rapidly advancing and highly specialized organization.  Clinicians will present and discuss this information in a multi-specialty setting. Clinicians will be informed and challenged across the organization to reach beyond their own specialization and role, and support higher levels of learning and competence for themselves, teams, and functions.

Session formats will vary between didactic presentations, panel discussions, and debates. All sessions will allow live attendees the opportunity to interact with the presenters and ask questions, thus supporting active learning.


Course Director: Colin D. Weekes, MD, PhD

For questions regarding the registration process, please contact Mass General Brigham Office of Continuing Professional Development at partnerscpd@partners.org.

You may print individual certificates throughout the year; your cumulative list of sessions attended is accessible on your transcript.


This session will broadcast outside of Mass General Brigham

Target Audience

This activity is intended for medical professionals in the field of oncology.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Evaluate recent advances or controversies in hematology/oncology treatment, clinical research and/or basic science investigation presented in this conference
  2. Assess opportunities to integrate information, tools or practices presented in this conference into how you deliver or support research and patient care
  3. Incorporate new information or perspectives from this conference into specific aspects of your responsibilities in patient care, research or the system in which you work
  4. Recognize evolving landscape of cancer care worldwide

Additional Information

Provided by: 

Mass General Brigham

Course summary
Course opens: 
09/15/2022
Course expires: 
06/30/2023
Cost:
$0.00

Schedule:

Date

Subject

Speaker

September 15, 2022

Leveraging Opportunities to Facilitate Inclusive Cancer Drug Development

Lola Fashoyin-Aje, MD, MPH

October 6, 2022    

Extending Immunotherapy Combinations in Gastroesophageal Cancer: How, What and When?

Ian Chau, MD, FRCP

October 13, 2022

New Considerations for Immunotherapy in Sarcoma

Seth M. Pollack, MD

October 27, 2022

Kidney Cancer: Bench to Bedside and Back

James Brugarolas, MD, PhD

November 3, 2022

Debate: Adjuvant/Neoadjuvant Immune Checkpoint Inhibitor Therapy

Rodabe Amaria, MD

November 10, 2022

TLR9 Agonists in Melanoma and Other Cancers: Current Development, Next Steps

Diwakar Davar, MD

December 1, 2022

The Chabner Pioneers in Oncology Lectureship: Translating Aging Biology Into Patient Care
*please note this session is not eligible for CME credit

Norman Sharpless, MD

Course Director

Colin D. Weekes, MD, PhD
Director, Pancreatic Cancer Research,
Mass General Cancer Center;
Associate Professor of Medicine,
Harvard Medical School


Disclosure Summary of Relevant Financial Relationships

INELIGIBLE COMPANIES
Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors                             
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers

For more information: https://accme.org/faq/what-accmes-definition-ineligible-company

MITIGATION STRATEGIES
Mass General Brigham has implemented a process to mitigate relevant financial relationships for this continuing education (CE) activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public. 

The following planners reported no relevant financial relationship with an ineligible company:
Colin D. Weekes, MD, MPH 

 

ACCREDITATION

In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA PRA Category 1 CreditTM
Mass General Brigham designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.